Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings

BACKGROUND: The sustainable use of HAART within the sub-Saharan and other developing world settings faces the emerging challenge of drug resistance. Nucleoside reverse transcriptase inhibitors (NRTI) form the backbone of HAART and preserving their “antiviral efficacy” is thus critical to sustainable...

Descripción completa

Detalles Bibliográficos
Autores principales: Wayengera, Misaki, Kajumbula, Henry, Byarugaba, Wilson
Formato: Texto
Lenguaje:English
Publicado: Bentham Open 2008
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627514/
https://www.ncbi.nlm.nih.gov/pubmed/19274067
http://dx.doi.org/10.2174/1874613600802010078
_version_ 1782163543793074176
author Wayengera, Misaki
Kajumbula, Henry
Byarugaba, Wilson
author_facet Wayengera, Misaki
Kajumbula, Henry
Byarugaba, Wilson
author_sort Wayengera, Misaki
collection PubMed
description BACKGROUND: The sustainable use of HAART within the sub-Saharan and other developing world settings faces the emerging challenge of drug resistance. Nucleoside reverse transcriptase inhibitors (NRTI) form the backbone of HAART and preserving their “antiviral efficacy” is thus critical to sustainable HAART use. METHODS: A systematic review of the “mechanisms of evolution” of resistance to NRTI at the HIV genome level, and the phenotypic manifestations on drug pharmacokinetics was done. CONCLUSION: This paper provides an evidence based account of how the knowledge of pharmacogenomics may be exploited to tackle NRTI resistance within limited resource.
format Text
id pubmed-2627514
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Bentham Open
record_format MEDLINE/PubMed
spelling pubmed-26275142009-03-09 Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings Wayengera, Misaki Kajumbula, Henry Byarugaba, Wilson Open AIDS J Article BACKGROUND: The sustainable use of HAART within the sub-Saharan and other developing world settings faces the emerging challenge of drug resistance. Nucleoside reverse transcriptase inhibitors (NRTI) form the backbone of HAART and preserving their “antiviral efficacy” is thus critical to sustainable HAART use. METHODS: A systematic review of the “mechanisms of evolution” of resistance to NRTI at the HIV genome level, and the phenotypic manifestations on drug pharmacokinetics was done. CONCLUSION: This paper provides an evidence based account of how the knowledge of pharmacogenomics may be exploited to tackle NRTI resistance within limited resource. Bentham Open 2008-11-05 /pmc/articles/PMC2627514/ /pubmed/19274067 http://dx.doi.org/10.2174/1874613600802010078 Text en © Wayengera et al.; Licensee Bentham Open. http://creativecommons.org/licenses/by-nc/3.0/ This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Wayengera, Misaki
Kajumbula, Henry
Byarugaba, Wilson
Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings
title Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings
title_full Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings
title_fullStr Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings
title_full_unstemmed Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings
title_short Harnessing Pharmacogenomics to Tackle Resistance to the “Nucleoside Reverse Trancripatse Inhibitor” Backbone of Highly Active Antiretroviral Therapy in Resource Limited Settings
title_sort harnessing pharmacogenomics to tackle resistance to the “nucleoside reverse trancripatse inhibitor” backbone of highly active antiretroviral therapy in resource limited settings
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627514/
https://www.ncbi.nlm.nih.gov/pubmed/19274067
http://dx.doi.org/10.2174/1874613600802010078
work_keys_str_mv AT wayengeramisaki harnessingpharmacogenomicstotackleresistancetothenucleosidereversetrancripatseinhibitorbackboneofhighlyactiveantiretroviraltherapyinresourcelimitedsettings
AT kajumbulahenry harnessingpharmacogenomicstotackleresistancetothenucleosidereversetrancripatseinhibitorbackboneofhighlyactiveantiretroviraltherapyinresourcelimitedsettings
AT byarugabawilson harnessingpharmacogenomicstotackleresistancetothenucleosidereversetrancripatseinhibitorbackboneofhighlyactiveantiretroviraltherapyinresourcelimitedsettings

Ejemplares similares